312 related articles for article (PubMed ID: 25956172)
21. Assessing BRCA carrier probabilities in extended families.
Barcenas CH; Hosain GM; Arun B; Zong J; Zhou X; Chen J; Cortada JM; Mills GB; Tomlinson GE; Miller AR; Strong LC; Amos CI
J Clin Oncol; 2006 Jan; 24(3):354-60. PubMed ID: 16421416
[TBL] [Abstract][Full Text] [Related]
22. Prospective validation of the BOADICEA multifactorial breast cancer risk prediction model in a large prospective cohort study.
Yang X; Eriksson M; Czene K; Lee A; Leslie G; Lush M; Wang J; Dennis J; Dorling L; Carvalho S; Mavaddat N; Simard J; Schmidt MK; Easton DF; Hall P; Antoniou AC
J Med Genet; 2022 Dec; 59(12):1196-1205. PubMed ID: 36162852
[TBL] [Abstract][Full Text] [Related]
23. BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface.
Lee AJ; Cunningham AP; Kuchenbaecker KB; Mavaddat N; Easton DF; Antoniou AC; ;
Br J Cancer; 2014 Jan; 110(2):535-45. PubMed ID: 24346285
[TBL] [Abstract][Full Text] [Related]
24. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
[TBL] [Abstract][Full Text] [Related]
25. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction.
Heemskerk-Gerritsen BA; Seynaeve C; van Asperen CJ; Ausems MG; Collée JM; van Doorn HC; Gomez Garcia EB; Kets CM; van Leeuwen FE; Meijers-Heijboer HE; Mourits MJ; van Os TA; Vasen HF; Verhoef S; Rookus MA; Hooning MJ;
J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25788320
[TBL] [Abstract][Full Text] [Related]
26. BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors.
Lee A; Mavaddat N; Wilcox AN; Cunningham AP; Carver T; Hartley S; Babb de Villiers C; Izquierdo A; Simard J; Schmidt MK; Walter FM; Chatterjee N; Garcia-Closas M; Tischkowitz M; Pharoah P; Easton DF; Antoniou AC
Genet Med; 2019 Aug; 21(8):1708-1718. PubMed ID: 30643217
[TBL] [Abstract][Full Text] [Related]
27. Selecting a BRCA risk assessment model for use in a familial cancer clinic.
Panchal SM; Ennis M; Canon S; Bordeleau LJ
BMC Med Genet; 2008 Dec; 9():116. PubMed ID: 19102775
[TBL] [Abstract][Full Text] [Related]
28. Discriminatory accuracy and potential clinical utility of genomic profiling for breast cancer risk in BRCA-negative women.
Comen E; Balistreri L; Gönen M; Dutra-Clarke A; Fazio M; Vijai J; Stadler Z; Kauff N; Kirchhoff T; Hudis C; Offit K; Robson M
Breast Cancer Res Treat; 2011 Jun; 127(2):479-87. PubMed ID: 20957429
[TBL] [Abstract][Full Text] [Related]
29. Validation of a breast cancer risk prediction model based on the key risk factors: family history, mammographic density and polygenic risk.
Allman R; Mu Y; Dite GS; Spaeth E; Hopper JL; Rosner BA
Breast Cancer Res Treat; 2023 Apr; 198(2):335-347. PubMed ID: 36749458
[TBL] [Abstract][Full Text] [Related]
30. Predictability of BRCA1/2 mutation status in patients with ovarian cancer: How to select women for genetic testing in middle-income countries.
Teixeira N; Maistro S; Del Pilar Estevez Diz M; Mourits MJ; Oosterwijk JC; Folgueira MAK; de Bock GH
Maturitas; 2017 Nov; 105():113-118. PubMed ID: 28619461
[TBL] [Abstract][Full Text] [Related]
31. Benign breast disease increases breast cancer risk independent of underlying familial risk profile: Findings from a Prospective Family Study Cohort.
Zeinomar N; Phillips KA; Daly MB; Milne RL; Dite GS; MacInnis RJ; Liao Y; Kehm RD; Knight JA; Southey MC; Chung WK; Giles GG; McLachlan SA; Friedlander ML; Weideman PC; Glendon G; Nesci S; ; Andrulis IL; Buys SS; John EM; Hopper JL; Terry MB
Int J Cancer; 2019 Jul; 145(2):370-379. PubMed ID: 30725480
[TBL] [Abstract][Full Text] [Related]
32. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Offit K; Foulkes W; Robson ME; Wacholder S; Eng CM; Karp SE; Begg CB
Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):467-73. PubMed ID: 11352856
[TBL] [Abstract][Full Text] [Related]
33. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
[TBL] [Abstract][Full Text] [Related]
34. Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation.
Bernholtz S; Laitman Y; Kaufman B; Paluch Shimon S; Friedman E
Breast Cancer Res Treat; 2011 Sep; 129(2):557-63. PubMed ID: 21499684
[TBL] [Abstract][Full Text] [Related]
35. Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers?
Bernholtz S; Laitman Y; Kaufman B; Shimon-Paluch S; Friedman E
Breast Cancer Res Treat; 2012 Apr; 132(2):669-73. PubMed ID: 22113258
[TBL] [Abstract][Full Text] [Related]
36. Prospective Evaluation of the Addition of Polygenic Risk Scores to Breast Cancer Risk Models.
Li SX; Milne RL; Nguyen-Dumont T; Wang X; English DR; Giles GG; Southey MC; Antoniou AC; Lee A; Li S; Winship I; Hopper JL; Terry MB; MacInnis RJ
JNCI Cancer Spectr; 2021 Jun; 5(3):. PubMed ID: 33977228
[TBL] [Abstract][Full Text] [Related]
37. Validation of three BRCA1/2 mutation-carrier probability models Myriad, BRCAPRO and BOADICEA in a population-based series of 183 German families.
Schneegans SM; Rosenberger A; Engel U; Sander M; Emons G; Shoukier M
Fam Cancer; 2012 Jun; 11(2):181-8. PubMed ID: 22160602
[TBL] [Abstract][Full Text] [Related]
38. Multicenter surveillance of women at high genetic breast cancer risk using mammography, ultrasonography, and contrast-enhanced magnetic resonance imaging (the high breast cancer risk italian 1 study): final results.
Sardanelli F; Podo F; Santoro F; Manoukian S; Bergonzi S; Trecate G; Vergnaghi D; Federico M; Cortesi L; Corcione S; Morassut S; Di Maggio C; Cilotti A; Martincich L; Calabrese M; Zuiani C; Preda L; Bonanni B; Carbonaro LA; Contegiacomo A; Panizza P; Di Cesare E; Savarese A; Crecco M; Turchetti D; Tonutti M; Belli P; Maschio AD;
Invest Radiol; 2011 Feb; 46(2):94-105. PubMed ID: 21139507
[TBL] [Abstract][Full Text] [Related]
39. Bias Correction Methods Explain Much of the Variation Seen in Breast Cancer Risks of BRCA1/2 Mutation Carriers.
Vos JR; Hsu L; Brohet RM; Mourits MJ; de Vries J; Malone KE; Oosterwijk JC; de Bock GH
J Clin Oncol; 2015 Aug; 33(23):2553-62. PubMed ID: 26150446
[TBL] [Abstract][Full Text] [Related]
40. Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study.
Giannakeas V; Lubinski J; Gronwald J; Moller P; Armel S; Lynch HT; Foulkes WD; Kim-Sing C; Singer C; Neuhausen SL; Friedman E; Tung N; Senter L; Sun P; Narod SA
Breast Cancer Res Treat; 2014 Aug; 147(1):113-8. PubMed ID: 25082516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
